Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia
In this study, using behavioral, immunohistochemical, electrophysiological and microdialysis techniques, we examined the mechanism by which ASP5736, a novel and selective 5-HT5A receptor antagonist, exerts a positive effect in animal models of cognitive impairment. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 20, 2018 Category: Psychiatry & Psychology Authors: Mayako Yamazaki, Noriyuki Yamamoto, Junko Yarimizu, Mayuko Okabe, Ai Moriyama, Masako Furutani, Monica M. Marcus, Torgny H. Svensson, Katsuya Harada Source Type: research
Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine
Three types of antipsychotics, typical (e.g. haloperidol), atypical (e.g. clozapine), and dopamine partial agonist (e.g. aripiprazole), are administered for treatment of schizophrenia. These antipsychotics have different efficacy and side-effect profiles. We investigated whether aripiprazole, clozapine, and haloperidol differentially regulate the dendritic spine through the AKT-GSK-3 beta cascade. Dissociated cortical neurons from Sprague-Dawley rats were prepared and cultured for 28 days. Aripiprazole, clozapine, or haloperidol was administered to the rat cortical neurons. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 20, 2018 Category: Psychiatry & Psychology Authors: Manabu Takaki, Masafumi Kodama, Yutaka Mizuki, Hiroki Kawai, Bunta Yoshimura, Makiko Kishimoto, Shinji Sakamoto, Yuko Okahisa, Norihito Yamada Source Type: research
The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers
Safety, tolerability and pharmacokinetics of BI 409306, a potent and selective phosphodiesterase 9A inhibitor, were assessed in healthy subjects in three Phase I, within-dose group, double-blind trials. Trial 1 randomised young and elderly subjects to receive BI 409306 25, 50, 100 mg, placebo once daily (OD) or BI 409306 50 mg twice daily (young) for 14 days. Trial 2 randomised young poor metabolisers (PM) of cytochrome P450 isoform 2C19 (CYP2C19) and elderly subjects to receive BI 409306 25, 50 mg or placebo OD for 14 days. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 19, 2018 Category: Psychiatry & Psychology Authors: Viktoria Moschetti, Maria Kim, Michael Sand, Glen Wunderlich, Grit Andersen, Ulrich Feifel, In-Jin Jang, Wolfgang Timmer, Holger Rosenbrock, Katja Boland Source Type: research
The need for patient-tailored dosing of baclofen in future clinical trials ☆
We enjoyed reading Thompson et al. ’s systematic review of baclofen dosing protocols for treating alcohol use disorder (AUD) in observational studies. The most recent double-blind randomized clinical trials on baclofen for treating AUD have had disappointing results, even at high doses (Beraha et al., 2016). This has led some autho rs to conclude that the drug should not be used. Based on their review of observational studies, Thompson et al. rightfully concluded that it was impossible to associate dose with effectiveness because of good outcomes reported at both low and high doses. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 16, 2018 Category: Psychiatry & Psychology Authors: Marie Costa, Benjamin Rolland, Patrizia Carrieri Source Type: research
Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies
In the second part we focus on two treatment strategies that may overcome the main limitations of current antidepressant drugs. First, we review the experimental and clinical evidence supporting the use of glutamatergic drugs as fast-acting antidepressants. Secondly, we review the involvement of microRNAs (miRNAs) in the pathophysiology of major depressive disorder (MDD) and the use of small RNAs (e.g.., small interfering RNAs or siRNAs) to knockdown genes in monoaminergic and non-monoaminergic neurons and induce antidepressant-like responses in experimental animals. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 8, 2018 Category: Psychiatry & Psychology Authors: F. Artigas, P. Celada, A. Bortolozzi Tags: REVIEW Source Type: research
A novel mechanism of depression: role for connexins
Major depressive disorder (MDD) is a chronic and debilitating illness that affects over 350 million people worldwide; however, current treatments have failed to cure or prevent the progress of depression. Increasing evidence suggests a crucial role for connexins in MDD. In this review, we have summarised recent accomplishments regarding the role of connexins, gap junctions, and hemichannels in the aetiology of MDD, and discussed the limitations of current research. A blockage of gap junctions or hemichannels induces depressive behaviour. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 5, 2018 Category: Psychiatry & Psychology Authors: Cong-Yuan Xia, Zhen-Zhen Wang, Tohru Yamakuni, Nai-Hong Chen Tags: REVIEW Source Type: research
Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD
We examined whether chronic treatment with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (0.2, 0.3, 0.4 mg/kg, i.p.) or the CB1/2 receptor agonist WIN55,212-2 (0.25, 0.5 mg/kg, i.p.) injected for 3 weeks to rats exposed to the shock and reminders model of PTSD would attenuate post-stress symptoms and affect basolateral amygdala (BLA) and CA1 CB1 receptors. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 5, 2018 Category: Psychiatry & Psychology Authors: Sharon Fidelman, Tomer Mizrachi Zer-Aviv, Rachel Lange, Cecilia J. Hillard, Irit Akirav Source Type: research
A novel mechanism of depression: role for connexins
Major depressive disorder (MDD) is a chronic and debilitating illness that affects over 350 million people worldwide; however, current treatments have failed to cure or prevent the progress of depression. Increasing evidence suggests a crucial role for connexins in MDD. In this review, we have summarised recent accomplishments regarding the role of connexins, gap junctions, and hemichannels in the aetiology of MDD, and discussed the limitations of current research. A blockage of gap junctions or hemichannels induces depressive behaviour. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 5, 2018 Category: Psychiatry & Psychology Authors: Cong-Yuan Xia, Zhen-Zhen Wang, Tohru Yamakuni, Nai-Hong Chen Tags: REVIEW Source Type: research
Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD
We examined whether chronic treatment with the fatty acid amide hydrolase (FAAH) inhibitor URB597 (0.2, 0.3, 0.4 mg/kg, i.p.) or the CB1/2 receptor agonist WIN55,212-2 (0.25, 0.5 mg/kg, i.p.) injected for 3 weeks to rats exposed to the shock and reminders model of PTSD would attenuate post-stress symptoms and affect basolateral amygdala (BLA) and CA1 CB1 receptors. (Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - March 5, 2018 Category: Psychiatry & Psychology Authors: Sharon Fidelman, Tomer Mizrachi Zer-Aviv, Rachel Lange, Cecilia J. Hillard, Irit Akirav Source Type: research
Editorial Board
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - February 28, 2018 Category: Psychiatry & Psychology Source Type: research
ECNP Calendar of Meetings
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - February 28, 2018 Category: Psychiatry & Psychology Source Type: research
Contents
(Source: European Neuropsychopharmacology)
Source: European Neuropsychopharmacology - February 28, 2018 Category: Psychiatry & Psychology Source Type: research
